JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 3 filers reported holding JUNO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $104,000 | +35.1% | 2,282 | +33.6% | 0.00% | 0.0% |
| Q3 2017 | $77,000 | +63.8% | 1,708 | +8.6% | 0.00% | +100.0% |
| Q2 2017 | $47,000 | +176.5% | 1,573 | +101.7% | 0.00% | 0.0% |
| Q1 2017 | $17,000 | +240.0% | 780 | +226.4% | 0.00% | – |
| Q4 2016 | $5,000 | -28.6% | 239 | +3.9% | 0.00% | – |
| Q3 2016 | $7,000 | -22.2% | 230 | 0.0% | 0.00% | – |
| Q2 2016 | $9,000 | – | 230 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |